A controlled trial of a human papillomavirus type 16 vaccine.
暂无分享,去创建一个
C. Wheeler | K. Ault | K. Jansen | L. Koutsky | Darron R Brown | E. Barr | Frances B. Alvarez | L. Chiacchierini | Darron R. Brown | F. Alvarez | Darron R. Brown | C. Wheeler
[1] M. Sherman,et al. Seroreactivity to human papillomavirus types 16, 18, 31, and 45 virus-like particles in a case-control study of cervical squamous intraepithelial lesions. , 1999, The Journal of infectious diseases.
[2] R. Schlegel,et al. Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[3] V. Moreno,et al. Prevalence of Human Papillomavirus in Cervical Cancer: a Worldwide Perspective , 1995 .
[4] J. van Hattum,et al. An open study of subcutaneous administration of inactivated hepatitis A vaccine (VAQTA) in adults: safety, tolerability, and immunogenicity. , 2001, Vaccine.
[5] Steven Bird,et al. A Randomized Trial of Alternative Two- and Three-Dose Hepatitis B Vaccination Regimens in Adolescents: Antibody Responses, Safety, and Immunologic Memory , 2001, Pediatrics.
[6] M. Hagensee,et al. Self-assembly of human papillomavirus type 1 capsids by expression of the L1 protein alone or by coexpression of the L1 and L2 capsid proteins , 1993, Journal of virology.
[7] Y. L. Lin,et al. Cottontail rabbit papillomavirus L1 protein-based vaccines: protection is achieved only with a full-length, nondenatured product , 1993, Journal of virology.
[8] C. Wheeler,et al. Neutralization of human papillomavirus type 11 (HPV-11) by serum from women vaccinated with yeast-derived HPV-11 L1 virus-like particles: correlation with competitive radioimmunoassay titer. , 2001, The Journal of infectious diseases.
[9] K. Jansen,et al. Human papillomavirus type 11 (HPV-11) neutralizing antibodies in the serum and genital mucosal secretions of African green monkeys immunized with HPV-11 virus-like particles expressed in yeast. , 1997, The Journal of infectious diseases.
[10] N. Kiviat,et al. Concurrent and sequential acquisition of different genital human papillomavirus types. , 2000, The Journal of infectious diseases.
[11] I. Frazer,et al. Expression of vaccinia recombinant HPV 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles. , 1991, Virology.
[12] A. Moscicki,et al. Risks for incident human papillomavirus infection and low-grade squamous intraepithelial lesion development in young females. , 2001, JAMA.
[13] H. Hausen. Immortalization of human cells and their malignant conversion by high risk human papillomavirus genotypes. , 1999 .
[14] R. Karron,et al. Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine. , 2001, Journal of the National Cancer Institute.
[15] Diane Solomon,et al. The Bethesda System for Reporting Cervical/Vaginal Cytologic Diagnoses , 1992, Springer US.
[16] I. Chan,et al. Exact power and sample size for vaccine efficacy studies , 1998 .
[17] K. Jansen,et al. Antibody, cytokine and cytotoxic T lymphocyte responses in chimpanzees immunized with human papillomavirus virus-like particles. , 2001, Vaccine.
[18] N. Kiviat,et al. Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection. , 2000, The Journal of infectious diseases.
[19] D. Lowy,et al. A virus-like particle enzyme-linked immunosorbent assay detects serum antibodies in a majority of women infected with human papillomavirus type 16. , 1994, Journal of the National Cancer Institute.
[20] Shalini L Kulasingam,et al. Evaluation of human papillomavirus testing in primary screening for cervical abnormalities: comparison of sensitivity, specificity, and frequency of referral. , 2002, JAMA.
[21] C. Meijer,et al. Relation of human papilloma virus status to cervical lesions and consequences for cervical-cancer screening: a prospective study , 1999, The Lancet.
[22] A. Reingold,et al. Genital human papillomavirus infection in female university students as determined by a PCR‐based method , 1991, JAMA.
[23] N. Christensen,et al. Antibody-mediated neutralization in vivo of infectious papillomaviruses , 1990, Journal of virology.
[24] F. Wiklund,et al. Type-specific persistence of human papillomavirus DNA before the development of invasive cervical cancer. , 1999, The New England journal of medicine.
[25] L. Koutsky,et al. Human papillomavirus testing for triage of women with cytologic evidence of low-grade squamous intraepithelial lesions: baseline data from a randomized trial. , 2000 .
[26] R. Burk,et al. Natural history of cervicovaginal papillomavirus infection in young women , 1998 .
[27] M. Rosolowsky,et al. Vaccination with yeast-expressed cottontail rabbit papillomavirus (CRPV) virus-like particles protects rabbits from CRPV-induced papilloma formation. , 1995, Vaccine.
[28] R. Burk,et al. Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia. , 1995, Journal of the National Cancer Institute.